China Resources Pharmaceutical Group Limited (3320.HK)
HKD 5.46
(-0.18%)
HKD 5.46
(-0.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 15.43 Billion HKD | 10.4% |
| 2022 | 15.47 Billion HKD | 15.69% |
| 2021 | 11.94 Billion HKD | 10.59% |
| 2020 | 12.46 Billion HKD | 5.05% |
| 2019 | 12.57 Billion HKD | -13.14% |
| 2018 | 13.65 Billion HKD | 11.38% |
| 2017 | 10.73 Billion HKD | 12.97% |
| 2016 | 9.95 Billion HKD | 3.93% |
| 2015 | 9.14 Billion HKD | -10.36% |
| 2014 | 8.32 Billion HKD | 5.09% |
| 2013 | 7.71 Billion HKD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 9.32 Billion HKD | 0.0% |
| 2023 Q4 | 5.69 Billion HKD | 0.0% |
| 2023 FY | - HKD | 10.4% |
| 2023 Q2 | 8.75 Billion HKD | 0.0% |
| 2022 Q2 | 8.22 Billion HKD | 0.0% |
| 2022 FY | - HKD | 15.69% |
| 2022 Q4 | 5.73 Billion HKD | 0.0% |
| 2021 Q2 | 6.77 Billion HKD | 0.0% |
| 2021 Q4 | 5.29 Billion HKD | 0.0% |
| 2021 FY | - HKD | 10.59% |
| 2020 FY | - HKD | 5.05% |
| 2020 Q4 | 4.69 Billion HKD | 0.0% |
| 2020 Q2 | 6.21 Billion HKD | 0.0% |
| 2019 Q2 | 6.6 Billion HKD | 0.0% |
| 2019 FY | - HKD | -13.14% |
| 2019 Q4 | 3.78 Billion HKD | 0.0% |
| 2018 FY | - HKD | 11.38% |
| 2018 Q2 | 6.43 Billion HKD | 0.0% |
| 2018 Q4 | 5.52 Billion HKD | 0.0% |
| 2017 FY | - HKD | 12.97% |
| 2017 Q2 | 5.68 Billion HKD | 0.0% |
| 2017 Q4 | 5.05 Billion HKD | 0.0% |
| 2016 FY | - HKD | 3.93% |
| 2016 Q4 | 4.34 Billion HKD | 0.0% |
| 2016 Q2 | 5.16 Billion HKD | 0.0% |
| 2015 Q2 | 5.29 Billion HKD | 0.0% |
| 2015 FY | - HKD | -10.36% |
| 2015 Q4 | 3.84 Billion HKD | 0.0% |
| 2014 Q4 | 2.05 Billion HKD | 8.6% |
| 2014 Q3 | 1.89 Billion HKD | 0.0% |
| 2014 Q2 | 1.89 Billion HKD | 0.0% |
| 2014 Q1 | 1.89 Billion HKD | 0.0% |
| 2014 FY | - HKD | 5.09% |
| 2013 Q3 | 1.76 Billion HKD | 0.0% |
| 2013 FY | - HKD | 0.0% |
| 2013 Q2 | 1.76 Billion HKD | 0.0% |
| 2013 Q1 | 1.76 Billion HKD | 0.0% |
| 2013 Q4 | 1.89 Billion HKD | 7.08% |
| 2012 Q4 | 1.76 Billion HKD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | -10159.91% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | -420.162% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 12013.916% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | -13459.908% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 30821.105% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -13951.087% |
| Essex Bio-Technology Limited | 418.37 Million HKD | -3588.277% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -20036.109% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 59066.349% |
| SSY Group Limited | 2.11 Billion HKD | -629.747% |
| JBM (Healthcare) Limited | 204.39 Million HKD | -7449.735% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | -3489.242% |